Prostate Cancer Prevention

Jack Cuzick, Mangesh A. Thorat (Herausgeber)

Buch | Softcover

VIII, 169 Seiten

2016 | 1. Softcover reprint of the original 1st ed. 2014
Springer Berlin (Verlag)
978-3-662-52443-5 (ISBN)

Artikel merken

Prostate cancer is by far the most common cancer in men and the second leading cause of death due to cancer. It comprises a mixed group of tumours displaying varying clinical behaviour: while some have a very aggressive course, others are rather indolent. Prevention of prostate cancer and discrimination between aggressive and indolent forms are important clinical goals and the acquisition of significant new evidence on means of achieving these aims makes this book particularly timely. A wide range of topics are covered by leading authorities in the field. The biology and natural history of prostate cancer are reviewed and the role of lifestyle and dietary factors, assessed. Detailed attention is paid to risk prediction biomarkers and to the role of novel high-throughput nucleic acid-based technologies in improving risk prediction and thereby allowing tailored approaches to cancer prevention. Potential means of chemoprevention of prostate cancer are also reviewed in depth, covering the very positive new data on the impact of aspirin as well as evidence regarding 5 -reductase inhibitors, DFMO and lycopene. Guidance is provided on the differentiation of aggressive from indolent disease and the policy and research implications of recent findings are examined. This book will be of interest to both clinicians and researchers.

Biology and natural history of prostate cancer.- Nutrition and prostate cancer.- Prostate cancer chemoprevention.- Lifestyle and dietary factors.- GWAS in prostate cancer predisposition and application to screening and prevention.- Risk prediction biomarkers - CCP.- Risk prediction biomarkers - TMPRSS2-ERG.- Risk prediction biomarkers - PCA3.- Risk adapted chemoprevention for PCa.- Outlook for 5 reductase inhibitors in prostate cancer prevention.- Prostate cancer chemoprevention: Aspirin.- Prostate cancer chemoprevention: DFMO.- Prostate cancer chemoprevention: Lycopene.- Distinguishing aggressive from indolent prostate cancer.- Prognosis and Management of low grade disease - Management of Gleason 6.- Prostate cancer prevention: Policy & Research implications.

From the reviews:

"Part of the Recent Advances in Cancer Research series, this book's title suggests that it tackles prevention of prostate cancer. ... scientists and clinicians who deal with prostate cancer are the main audience. ... The discussion of agent development and strategies is very useful to anyone looking to tackle the challenging area of prostate cancer chemoprevention." (Leonard G. Gomella, Doody's Book Reviews, May, 2014)

Erscheinungsdatum	15.09.2016
Reihe/Serie	Recent Results in Cancer Research
Zusatzinfo	VIII, 169 p. 11 illus., 4 illus. in color.
Verlagsort	Berlin
Sprache	englisch
Maße	155 x 235 mm
Themenwelt	Medizin / Pharmazie ► Medizinische Fachgebiete ► Onkologie
Themenwelt	Medizin / Pharmazie ► Medizinische Fachgebiete ► Urologie
Schlagworte	Biomarkers • Cancer Research • chemoprevention • early detection • Medicine • Oncology • Prostate Cancer • Risk-prevention • Urology • Urology and urogenital medicine
ISBN-10	3-662-52443-0 / 3662524430
ISBN-13	978-3-662-52443-5 / 9783662524435
Zustand	Neuware